Aldosterone and cardiovascular remodelling: Focus on myocardial failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 1, 2004, Pages 3-13

  Shieh, Frederick K ^a   Kotlyar, Eugene ^b   Sam, Flora ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c Division of Cardiology   (United States)

Author keywords

Aldosterone; Heart failure; Myocardial; Remodelling; Vascular

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; CALCINEURIN INHIBITOR; CANDESARTAN; CANRENONE; CORTICOSTEROID; CYCLOHEXIMIDE; CYCLOSPORIN A; DACTINOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; EPLERENONE; GLUCOCORTICOID ANTAGONIST; LOSARTAN; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; NEUROHORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLIDINE DITHIOCARBAMATE; SPIRONOLACTONE; TACROLIMUS; UNINDEXED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ALDOSTERONE RELEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; GYNECOMASTIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; MOUSE; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; RECEPTOR SENSITIVITY; REVIEW; SURVIVAL;

EID: 1842737277     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.005     Document Type: Review

References (149)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348: 2007-18.
2. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995;16(suppl N):103-06.
3. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
4. Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 1989;264:20961-7.
5. Mizuno Y, Yoshimura M, Yasue H et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7.
6. TsutamotoT, Wada A, Maeda K et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000;36:838-44.
7. Young MJ, Clyne CD, Cole TJ, Funder JW. Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 2001;86:5121-6.
8. Silvestre JS, Robert V, Heymes C et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.
9. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000;36:495-500.
10. Young MJ, Clyne CD, Cole TJ, Funder JW. Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 2001;86:5121-6.
11. Satoh M, Nakamura M, Saitoh H et al. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) 2002;102:381-6.
12. Yoshimura M, Nakamura S, Ito T et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002;87:3936-40.
13. Xiu JC, Wu P, Xu JP et al. Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone. J Endocrinol Invest 2002;25:463-8.
14. Hanawa H, Abe S, Hayashi M et al. Time course of gene expression in rat experimental autoimmune myocarditis. Clin Sci (Lond) 2002;103:623-32.
15. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000;85:2519-25.
16. Silvestre JS, Robert V, Heymes C et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.
17. Young MJ, Moussa L, Dilley R, Funder JW. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 2003;144:1121-5.
18. Takeda Y, Miyamori I, YonedaT et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.
19. White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 2003;88:2376-83.
20. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71:503-10.
21. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-82.
22. Bonvalet JP. Regulation of sodium transport by steroid hormones. Kidney Int 1998;65(suppl):S49-S56.
23. Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
24. White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997;18:135-56.
25. Slight S, Ganjam VK, Nonneman DJ, Weber KT. Glucocorticoid metabolism in the cardiac interstitium: 11 beta-hydroxysteroid dehydrogenase activity in cardiac fibroblasts. J Lab Clin Med 1993;122:180-7.
26. Kohler E, Bertschin S, Woodtli T, Resink T, Erne P. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res 1996;33:315-26.
27. Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK 1/2 signaling. Am J Physiol Heart Circ Physiol 2003;284:H176-H184.
28. Fiebeler A, Schmidt F, Muller DN et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001;37(2 Part 2):787-93.
29. Krug AW, Schuster C, Gassner B et al. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem 2002;277:45892-7.
30. Krug AW, Grossmann C, Schuster C et al. Aldosterone stimulates epidermal growth factor receptor (EGFR) expression. J Biol Chem 2003;278:43060-6.
31. Qin W, Rudolph AE, Bond BR et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003;93:69-76.
32. Hafezi-Moghadam A, Simoncini T, Yang E et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473-9.
33. Beggah AT, Escoubet B, Puttini S et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci USA 2002;99:7160-5.
34. Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun 1995;213:123-9.
35. Sato A, Liu JP, Funder JW. Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro. Endocrinology 1997;138:3410-16.
36. Good DW, George T, Watts BA 3rd. Aldosterone potentiates 1,25-dihydroxyvitamin D3 action in renal thick ascending limb via a nongenomic, ERK-dependent pathway. Am J Physiol Cell Physiol 2003;285:C1122-30.
37. Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83:3517-22.
38. Ball AM, Sole MJ. Oxidative stress and the pathogenesis of heart failure. Cardiol Clin 1998;16(4):665-6ix.
39. Keith ME, Jeejeebhoy KN, Langer A et al. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr 2001;73:219-24.
40. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000;3:417-24.
41. Singal PK, Khaper N, Farahmand F, Bello-Klein A. Oxidative stress in congestive heart failure. Curr Cardiol Rep 2000; 2:206-11.
42. Cesselli D, Jakoniuk I, Barlucchi L et al. Oxidative stressmediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001;89:279-86.
43. Tsutsui H, IdeT, Hayashidani S et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001;104: 134-6.
44. Haugen EN, Croatt AJ, Nath KA. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int 2000;58:144-52.
45. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
46. Wang HD, Pagano PJ, Du Y et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 1998;82:810-18.
47. Swei A, Lacy F, DeLano FA, Schmid-Schonbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension 1997;30:1628-33.
48. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95:588-93.
49. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 1999;33:1353-8.
50. Ide T, Tsutsui H, Kinugawa S et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999;85:357-63.
51. Nath R, Kumar D, Li T, Singal PK. Metallothioneins, oxidative stress and the cardiovascular system. Toxicology 2000; 155:17-26.
52. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000;101:1722-8.
53. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.
54. Schnackenberg CG, Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 1999;33(1 Pt 2):424-8.
55. Singal PK, Beamish RE, Dhalla NS. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol 1983;161:391-401.
56. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000;20: 2175-83.
57. Virdis A, Neves MF, Amiri F, Viel E,Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
58. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49-55.
59. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.
60. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24:183-8.
61. Tostes RC, Touyz RM, He G, Chen X, Schiffrin EL. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin Sci (Lond) 2002;103(suppl 48):25S-30S.
62. Cambiaggi C, Mencarelli M, Muscettola M, Grasso G. Gene expression of endothelin-1 (ET-1) and release of mature peptide by activated human neutrophils. Cytokine 2001; 14:230-3.
63. Scholz H, Kramer BK, Hamann M, Gotz KH, Kurtz A. Effects of endothelins on renin secretion from rat kidneys. Acta Physiol Scand 1995;155:173-82.
64. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300-07.
65. Keidar S, Hayek T, Kaplan M et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003;41:955-63.
66. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
67. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003;88:2364-72.
68. Anker SD, Chua TP, Ponikowski P et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96: 526-34.
69. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
70. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
71. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
72. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
73. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.
74. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65.
75. Cohn JN,Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
76. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.
77. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
78. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25: 563-75.
79. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.
80. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-7.
81. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002;106:2848-53.
82. Chun TY, Bloem LJ, Pratt JH. Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology 2003;144:1712-17.
83. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32:865-79.
84. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863-7.
85. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996;32:266-73.
86. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26: 809-20.
87. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988;4:93-126.
88. Alexander CM, Werb Z. Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1989;1:974-82.
89. Eitzman DT, McCoy RD, Zheng X et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97:232-7.
90. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992;20:67-73.
91. Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85:336-44.
92. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.
93. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002;143:4828-36.
94. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999;33:981-6.
95. Benitah JP, Vassort G. Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes. Circ Res 1999;85:1139-45.
96. Molkentin JD, Lu JR, Antos CL et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-28.
97. Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 2002;105:677-9.
98. Xiao F, Puddefoot JR, Vinson GP. Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J Endocrinol 2000;165:533-6.
99. Neumann S, Huse K, Semrau R et al. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002;39:756-60.
100. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000;141:1901-04.
101. Delles C, Schmidt BM, Muller HJ, Oehmer S, Klingbeil AU, Schmieder RE. Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol 2003;91: 297-301.
102. Wencker D, Chandra M, Nguyen K et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111:1497-504.
103. Leri A, Claudio PP, Li Q et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 1998; 101:1326-42.
104. De Angelis N, Fiordaliso F, Latini R et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 2002; 34:1655-65.
105. Ben Rhouma K, Schimchowitsch S, Stoeckel ME, Felix JM, Sakly M. [Implication of type II glucocorticoid receptors in aldosterone induced apoptosis of rat thymocytes]. Arch Physiol Biochem 1997;105:216-24.
106. McCullers DL, Sullivan PG, Scheff SW, Herman JP. Mifepristone protects CA1 hippocampal neurons following traumatic brain injury in rat. Neuroscience 2002;109:219-30.
107. Sam F, Kerstetter DL, Ooi H et al. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens 2004; 17:188-93.
108. Ramires FJ, Mansur A, Coelho O et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-11.
109. Hallstrom A, Pratt CM, Greene HL et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol 1995;25:1250-7.
110. Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol 1993;71:34A-39A.
111. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
112. Weber MA, Purdy RE. Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 1982;30:2009-17.
113. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-06.
114. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108:1831-8.
115. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
116. Epstein M, Buckalew V, Altamirano J, Roniker B, Krause S, Kleiman J. Eplerenone Reduces Proteinuria in Type II Diabetes Mellitus: Implications for Aldosterone Involvement in the Pathogenesis of Renal Dysfunction. JACC 2002;39(suppl 1): 249A.
117. Pitt B, Remme W, Zannad F, Neaton J et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
118. Rabasseda X, Silvestre J, Castaner J. Eplerenone: antihypertensive treatment of heart failure: aldosterone antagonist. Drugs Future 1999;24:488-501.
119. Funder JW. Aldosterone resurgens-letter from EPHESUS. J Clin Endocrinol Metab 2003;88:2373-5.
120. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996;27(3 Pt 2):481-90.
121. Pratt JH, Rebhun JF, Zhou L et al. Levels of mineralocorticoids in whites and blacks. Hypertension 1999;34:315-19.
122. Yancy CW. Heart failure in blacks: etiologic and epidemiologic differences. Curr Cardiol Rep 2001;3:191-7.
123. Flack JM, Oparil S, Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55.
124. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16.
125. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.
126. Takeda Y, Miyamori I, Yoneda T et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.
127. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994;269:24316-20.
128. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology 1997;138:3369-73.
129. Takeda Y, Miyamori I, Yoneda T et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995;25:170-3.
130. Patel PD, Sherman TG, Goldman DJ, Watson SJ. Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus. Mol Endocrinol 1989;3:1877-85.
131. Pearce P, Funder JW. High affinity aldosterone binding sites (type I receptors) in rat heart. Clin Exp Pharmacol Physiol 1987;14(11-12):859-66.
132. Takeda Y, Miyamori I, Inaba S et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997;29(1 Pt 1): 45-8.
133. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997;17:1152-6.
134. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269(4 Pt 1):E657-E662.
135. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 1995;290:69-73.
136. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002;103: 425-31.
137. Duprez DA, De Buyzere ML, Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-6.
138. Blacher J, Amah G, Girerd X et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10(12 Pt 1):1326-34.
139. White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 1995;21:437-442.
140. Kupari M, Hautanen A, Lankinen L et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569-75.
141. Brand E, Chatelain N, Mulatero P et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998;32:198-204.
142. Lajemi M, Labat C, Gautier S et al. Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens 2001;19:407-13.
143. Takai E, Akita H, Kanazawa K et al. Association between aldosterone synthase (CYP11B2) gene polymorphisin and left ventricular volume in patients with dilated cardiomyopathy. Heart 2002;88:649-50.
144. Tiago AD, Badenhorst D, Skudicky D et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 2002;54:584-9.
145. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996;137:4145-53.
146. Trueblood NA, Xie Z, Communal C et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001;88:1080-7.
147. Campos AH, Zhao Y, Pollman MJ, Gibbons GH. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res 2003;92:111-18.
148. Gerling IC, Sun Y, Ahokas RA et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003;285:H813-H821.
149. Ahokas RA, Warrington KJ, Gerling IC et al. Aldosteronism and Peripheral Blood Mononuclear Cell Activation. A Neuroendocrine-Immune Interface. Circ Res 2003;93:124-35.